CGRP & Migraine Research
Explore migraine research on CGRP biology, CGRP-targeted treatments, efficacy, safety and emerging therapeutics.
-
Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience.
Authors: Gomaa MA, Taha NA, Helmy SM, Farag SM, Moustafa RR Observational study
This study evaluated the real-world use of anti-CGRP therapies in Egypt. Researchers focused on effectiveness, tolerability, barriers to access, and treatment adherence. Eighty migraine patients participated…
-
Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program.
Authors: Gül S, Ong B, Trudeau S, Thompson N, Yuan H Observational study
In a study comparing treatments for migraine, researchers evaluated calcitonin gene-related peptide monoclonal antibodies, or CGRP mAbs, and onabotulinumtoxinA. They aimed to determine if CGRP mAbs were non-inferior…
-
[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].
Authors: Ishikawa T, Morota S, Shi B, Li Y, Iijima M Review
Migraine is a common neurological disorder that causes significant burden on individuals. Current treatments face challenges like contraindications and delayed effectiveness. Rimegepant is a new oral medication…
-
Galcanezumab in chronic migraine
Authors: Detke et al. Clinical trial
This study evaluated galcanezumab's effectiveness for preventing chronic migraines. Galcanezumab is a humanized monoclonal antibody targeting calcitonin gene-related peptide. It was tested in a phase 3, randomized…
MigraineMind Top 100 · #55 -
Evaluation of Galcanezumab for the Prevention of Episodic Migraine
Authors: Stauffer et al. Clinical trial
Migraine is a debilitating condition marked by severe headache attacks. Current treatments often reduce migraine frequency but can cause adverse effects. This study assessed galcanezumab's efficacy compared to…
MigraineMind Top 100 · #57 -
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Authors: Edvinsson et al. Review
Migraine treatment is entering a transformative era focused on CGRP-targeted therapies. These drugs target calcitonin gene-related peptide or its receptor, enhancing migraine management. Approval for several of these…
MigraineMind Top 100 · #12 -
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
Authors: Dodick et al. Clinical trial
Erenumab is a monoclonal antibody that targets the calcitonin gene-related peptide receptor. This study evaluated erenumab's effectiveness for preventing episodic migraines. Five hundred seventy-seven adults…
MigraineMind Top 100 · #52 -
A Controlled Trial of Erenumab for Episodic Migraine
Authors: Goadsby et al. Clinical trial
In this study, researchers evaluated erenumab for preventing episodic migraine. Erenumab is a monoclonal antibody that inhibits a specific receptor. Patients received a monthly injection of either 70 mg, 140 mg, or…
MigraineMind Top 100 · #17 -
Fremanezumab for the Preventive Treatment of Chronic Migraine
Authors: Silberstein et al. Clinical trial
Fremanezumab is a monoclonal antibody aimed at preventing chronic migraines. This study compared its effectiveness to placebo in a phase 3 trial. Patients with chronic migraines received one of three treatments. They…
MigraineMind Top 100 · #26 -
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Authors: Tepper et al. Clinical trial
The study explored erenumab's safety and efficacy in chronic migraine patients. Researchers conducted a phase 2, randomized, double-blind trial across 69 centers in North America and Europe. Participants were adults…
MigraineMind Top 100 · #32 -
Cgrp May Play A Causative Role in Migraine
Authors: Lassen et al. Clinical trial
Calcitonin gene-related peptide, or CGRP, is linked to migraine attacks. This study investigated if CGRP causes headaches or is a result of migraines. Twelve patients with migraine without aura participated in a…
MigraineMind Top 100 · #33